Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05411588 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT05411588 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 65 participants.
The verdict
NCT05411588, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) in healthy participants. This study is seeking participants who: * Are healthy as determined by medical evaluation. * Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Have a body mass index (BMI) of 17.5 to 32 kilogram per meter square - a total body weight of more than 50 kilograms (110 pounds) Participants will be divided randomly into 8 different groups. All participants will receive either one PF-07275315 or a harmless treatment that has no medical effect (placebo) intravenous (IV) infusion (given directly into a vein). Participants will take part in this study for up to 541 days. During this time, eligible participants will receive single increasing amounts of PF-07275315 or placebo. Increase will only occur if the sponsor agrees that the next dose is likely to have acceptable safety and tolerability. The follow-up visit will take place 271 days after first treatment.
Interventions
- DRUG Placebo
- DRUG PF-07275315
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-06-09 |
| Est. Completion | 2024-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05411588
The ClinicalTrials.gov registry entry for NCT05411588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05411588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05411588 about?
NCT05411588 is a clinical study titled "A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) in healthy participants. This study is seeking participants who: * Are healthy as determined by medical evaluation. * Are willing and able to comply with all scheduled visits, tre...
What is the current status of trial NCT05411588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2022-06-09. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT05411588?
The interventions under investigation include: Placebo (DRUG), PF-07275315 (DRUG).
Who is sponsoring clinical trial NCT05411588?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.